📰 Clinical Program News

Page 7 - Clinical Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Clinical Program. Real-time updates on events, politics, business and more.

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023

February 28, 2024

Strategic Progress Amidst Financial Challenges

Repare Therapeutics Inc Financial Performance Therapeutics Inc Clinical Programs Collaboration Agreement Clinical Program

Source: yahoo.com

Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

February 15, 2024

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of...

United States Peter Greenleaf Joe Miller Daniel Billen Common Shares Of The Company Drug Administration

Source: marketscreener.com

Viking Therapeutics Inc (VKTX) Reports Year-End Financials Highlighting Strong Cash Position ...

February 7, 2024

Key Developments and Financials from 2023 Earnings Report

Development Expenses Analysis Of Company Performance Therapeutics Inc Year End Cash Position Viking Therapeutics Administrative Expenses

Source: yahoo.com

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in ...

February 1, 2024

Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single doseA single dose of NTLA-2002 led to 95% mean reduction

United Kingdom Ian Karp Alina Li Matt Crenson John Leonard Drug Administration

Source: eagletribune.com

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Region

January 29, 2024

OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 29, 2024--

United States Kristina Allikmets Lauren Padovan Demyelinating Polyneuropathy European Academy Of Neurology Peripheral Nerve Society Peripheral Nerve Society

Source: eagletribune.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Business

January 29, 2024

OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 29, 2024--

United States Demyelinating Polyneuropathy Kristina Allikmets Lauren Padovan European Medicines Agency Peripheral Nerve Society

Source: valdostadailytimes.com

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 29, 2024 at 02:01 am EST

January 29, 2024

HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment...

United States Kristina Allikmets Demyelinating Polyneuropathy Research Development For Takeda Plasma Committee For Medicinal Products Human Use European Commission

Source: marketscreener.com

Takedas HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CIDP

January 29, 2024

Takeda TSE4502NYSETAK today announced that the European Commission EC approved HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy CIDP after stabilization with intravenous immunoglobulin therapy IVIG.

United States Kristina Allikmets Demyelinating Polyneuropathy European Medicines Agency Peripheral Nerve Society Clinical Program

Source: businesswireindia.com

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 29, 2024

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients…

United States Lauren Padovan Kristina Allikmets Demyelinating Polyneuropathy European Medicines Agency Postmedia Network Inc

Source: canada.com